Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6856 to 6870 of 7691 results

  1. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development [GID-TA10900] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    In development [GID-TA10728] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Diabetes - buccal insulin [ID311]

    Discontinued [GID-TAG244]

    Technology appraisal guidance
    Discontinued

  4. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued

  5. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued [GID-TAG496]

    Technology appraisal guidance
    Discontinued

  6. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued [GID-TAG494]

    Technology appraisal guidance
    Discontinued

  7. ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

    Discontinued [GID-TA10445]

    Technology appraisal guidance
    Discontinued

  8. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued [GID-TA10345]

    Technology appraisal guidance
    Discontinued

  9. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued [GID-TA10298]

    Technology appraisal guidance
    Discontinued

  10. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued [GID-TA10332]

    Technology appraisal guidance
    Discontinued

  11. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued [GID-TA10522]

    Technology appraisal guidance
    Discontinued

  12. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development [GID-TA10589] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    In development [GID-TA11421] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development [GID-TA10779] Expected publication date: TBC

    Technology appraisal guidance
    In development